In the News

Read the latest news on OCG to stay up-to-date on new research findings and important announcements.

CTD²
May 28, 2014

In a study published in Nature Medicine, CTD2 investigators modeled colorectal cancer in primary organoids derived from mouse colon. They used the organoid system to functionally study Insulin-...

CTD²
April 20, 2014

CTD2 bioinformaticians at Memorial Sloan Kettering Cancer Center developed an analysis tool called Statius to identify potential therapeutics to target patient-specific vulnerabilities. In tumors...

CTD²
April 02, 2014

Evaluation of Dependency DifferentialitY (EDDY) provides an alternative approach to differential expression-based analyses of data generated under multiple conditions.  It was developed by CTD2...

CTD²
December 03, 2013

Despite non-small cell lung cancers (NSCLC) being one of the most common cancers, current treatment strategies are limited and survival rates are extremely low. CTD2 investigators at the...

CTD²
November 29, 2013

CTD2 researchers at University of Texas Southwestern Medical Center determined the structure and biosynthetic pathways of a family of natural compounds that inhibit the discoidin domain receptor 2...

CTD²
May 28, 2013

A review by the CTD2 Center at Emory University entitled “Targeting protein-protein interactions as an anticancer strategy” was published [Epub ahead of print] on May 28 in the journal Trends in...

CGCI
May 22, 2013

Researchers from British Columbia Cancer Agency used whole genome sequencing to analyze 40 DLBCL cases and 13 cell lines in order to fill in the gaps of the complex landscape of DLBCL genomes....

TARGET
April 07, 2013

TARGET researchers presented their work on pediatric cancers at the AACR Annual Meeting 2013. The entire TARGET session is available free to the public on the AACR website:

CTD²
April 06, 2013

Dr. Daniela Gerhard Introduces Cancer Target Discovery and Development (CTD2) Scientific Session at AACR 2013

CGCI
March 04, 2013

Through RNA-seq and targeted exon sequencing analysis, investigators working in the CGCI program discovered FOXO1 frequently mutated in diffuse large B-cell lymphoma (DLBCL) cases. FOXO1 is a...

Pages